SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Unofficial reports that POET optical engines were featured in Foxconns photonics ecosystem at Hon Hai Tech Day have revived interest in the companys existing FIT collaboration. Bulls view the appearance as technical validation, while skeptics stress that a demo is not evidence of production orders and want clearer commercial updates as the shares remain weak.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A rebound in the TRUMP meme coin has prompted speculative calls for a pump or short squeeze, while the dominant discussion remains bearish: traders call it a pump-and-dump and point to steep losses among holders. Some remain bullish or say they are accumulating, but no specific confirmed catalyst for the move is apparent.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa has put FDA acceptance and the review timeline at the center of discussion. Traders are divided between optimism about approval and the drugs commercial potential and concern over regulatory risk, competitive pressure, and whether MoonLake can commercialize on its own.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention ahead of its Q3 report, with investors focused on AUVELITY sales and whether uptake for the Alzheimers agitation indication is accelerating. The sharp selloff has heightened concerns about prescription trends, launch execution and spending, while bulls argue that sampling and long-term-care channels may obscure demand and look to management for clearer data.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of expected Q3 results has put TGTX in focus, with traders watching BRIUMVIs sales momentum and guidance. Buyout and short-squeeze theories are also circulating, but remain speculation rather than confirmed catalysts.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter results, which beat expectations on growth led by Dupixent and Eylea HD, have driven a sharp share-price breakout. Traders are largely celebrating the report and bullish options activity, while some note that declining legacy Eylea sales remain a risk to watch.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is drawing attention amid a sharp, volatile pullback that traders link to weakness in growth and AI stocks, with Q3 earnings expectations adding uncertainty. The community is split between buying the dip on Ousters lidar and Physical AI opportunity and warning that shares could fall further.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is driving discussion, with traders debating whether broad tech and advertising-market concerns justify the decline despite the companys profitability and growth. Bulls describe the shares as oversold and undervalued, while bears worry about weaker ad demand, competition, or disappointing results; no single confirmed company-specific development dominates.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVAs stronger-than-expected quarterly results, including solid same-store sales and guest-traffic growth, fueled a sharp rebound and revived discussion of its store-expansion runway. Bulls see continued growth potential, while skeptics point to the stocks high valuation and pressure on restaurant spending.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

A sharp pullback after a strong run is driving discussion, with traders weighing profit-taking and broader weakness in AI-infrastructure stocks against the upcoming earnings report. Bulls see the decline as a buying opportunity given Aristas role in AI data-center networking, while others worry about further downside and whether spending expectations are too high.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DCTH I think DCTH beats big time this quarter. We know that at the last conference call on Aug 6th they hadn’t seen any summer slowdown yet, because they said so. We also know there was an acceleration of treatments per center in Q2 to 1.8 treatments per center per month.  At the same monthly run rate per center, we are looking at $30M US revenue plus European revenue of $1.5m that’s $31.5m for Q3, which is 55% revenue growth YOY. The street is at $25.84m That’s a headline beat of 22% and they’d have to raise FY guidance to $120M. The stock price should jump to over $18, unless the market is tanking. $14 is very cheap.

KNOW WHO YOU FOLLOW

StockTwits for iOS

Delcath Systems Inc

 I think DCTH beats big time this quarter. We know that at the last conference call on Aug 6th they hadn’t seen any summer slowdown yet, because they said so. We also know there was an acceleration of treatments per center in Q2 to 1.8 treatments per center per month.  At the same monthly run rate per center, we are looking at $30M US revenue plus European revenue of $1.5m that’s $31.5m for Q3, which is 55% revenue growth YOY. The street is at $25.84m That’s a headline beat of 22% and they’d have to raise FY guidance to $120M. The stock price should jump to over $18, unless the market is tanking. $14 is very cheap.

Gio W

@GioW I am at $29.1 m ($27.1 m US) , assuming new patient starts were 0.7 q1, 0.5 q2, 0.2 q3; 4 repeat procedures per new patient every 6 weeks @ $175K. 31 hospitals end of Q2 and 33 end of Q3. My model was accurate for Q2. I believe they will bring down hospital activations from 37 year end to 35. The pace of openings has been the only blemish

StockTwits Web

 I am at $29.1 m ($27.1 m US) , assuming new patient starts were 0.7 q1, 0.5 q2, 0.2 q3; 4 repeat procedures per new patient every 6 weeks @ $175K. 31 hospitals end of Q2 and 33 end of Q3. My model was accurate for Q2. I believe they will bring down hospital activations from 37 year end to 35. The pace of openings has been the only blemish